Alcohol consumption and cigarette smoke are risk factors for esophageal cancer, especially for multicentric carcinogenesis.
Alcohol consumption and cigarette smoke are risk factors for esophageal cancer, especially for multicentric carcinogenesis.
批准号:
17591451
负责人:
URAMOTO Hidetaka
金额:
$2.3万
依托单位国家:
日本
项目类别:
Grant-in-Aid for Scientific Research (C)
财政年份:
2005
资助国家:
日本
项目状态:
已结题
起止时间:
2005 至 2006
中文摘要
点击翻译按钮获取中文摘要
英文摘要
Alcohol metabolism: A loss of fragile histidine triad (FHIT) expression is associated not only with alcohol-induced esophageal carcinogenesis, but also with multicentric carcinogenesis, in the metabolic pathway of ethanol. Aldehyde dehydrogenase 2 (ALDH2) is a major enzyme for detoxification of acetaldehyde, and it is important for esophageal and ling carcinogenesis. Both inactive and active forms of ALDH2 are induced in the esophagus by heavy drinking and also support a hypothesis that ALDH2 deficiency might be a high-risk factor of esophageal cancer for the individuals having a heavy-drinking habit. The expression level of Cyp2e1 was increased in the liver from Aldh2-null mice. Therefore, Aldh2-null mice may be useful model animals for the investigation of alcohol metabolism and related diseases.Tobacco smoking: The methylation of p16 was more frequently observed in patients who were heavy smoker and with squamous cell carcinoma and than in never/ light smokers and adenocarinoma, respectively. The mutations in the epidermal growth factor receptor (EGFR) gene were more frequently observed in patients who smoked p20 pack-year, and in patients who quit at least 20 years before the date of diagnosis for lung cancer. The K-ras mutations were more frequently found in smokers than in never smokers, and in high-dose smokers than in low-dose smokers, suggesting that mutations of EGFR and k-ras might be strongly associated with exposure of tobacco smoking.
期刊论文(33)
专著(0)
科研奖励(0)
会议论文
登录
查看更多内容
A new mechanism for primary resistance to gefitinib in lung adenocarcinoma : The role of a novel G796A mutation in exon 20 of EGFR
肺腺癌吉非替尼原发耐药的新机制:EGFR外显子20中新型G796A突变的作用
DOI:
--
发表时间:
2007
期刊:
Anticancer Res (in press)
影响因子:
--
作者:
[斉藤真一, 山中潤一, 他, Oyama T, Sugaya M, Oyama T, Uramoto H]
通讯作者:
Uramoto H
DOI:
10.2741/2232
发表时间:
2007-01-01
期刊:
FRONTIERS IN BIOSCIENCE-LANDMARK
影响因子:
3.1
作者:
[Oyama, Tsunehiro, Sugio, Kenji, Yasumoto, Kosei]
通讯作者:
Yasumoto, Kosei
Effect of IgG produced by tumor-infiltrating B lymphocytes on hung tumor growth.
肿瘤浸润 B 淋巴细胞产生的 IgG 对悬挂肿瘤生长的影响。
DOI:
--
发表时间:
2006
期刊:
Anticancer Res. 26(3A)
影响因子:
--
作者:
[斉藤真一, 山中潤一, 他, Oyama T, Sugaya M, Oyama T, Uramoto H, Oyama T, Sugaya M, Uramoto H, Uramoto H, Uramoto H, Uramoto H, Morita M, Ozaki S, Nakata S, Sugio K, Yasuda M, Mizukami M]
通讯作者:
Mizukami M
A lack of prognostic significance regarding DeltaNp63 immunoreactivity in lung cancer.
DeltaNp63 免疫反应性对肺癌缺乏预后意义。
DOI:
--
发表时间:
2005
期刊:
Lung Cancer 50(1)
影响因子:
--
作者:
[斉藤真一, 山中潤一, 他, Oyama T, Sugaya M, Oyama T, Uramoto H, Oyama T, Sugaya M, Uramoto H, Uramoto H, Uramoto H, Uramoto H, Morita M, Ozaki S, Nakata S, Sugio K, Yasuda M, Mizukami M, Uramoto H, Mizukami M, Uramoto H, Uramoto H, Uramoto H, Morita M, Fukuyama T, Nakata S, Takenoyama M, Morita M, Oyama T, Oyama T, Morita M, Yoshimatsu T, Uramoto H, Iwata T]
通讯作者:
Iwata T
DOI:
10.1038/sj.bjc.6603040
发表时间:
2006-03-27
期刊:
British journal of cancer
影响因子:
8.8
作者:
[]
通讯作者:
共 25 条
Searching for molecular markers of postoperative recurrence after surgery for lung cancer and its clinical application
-
批准号:17K10803
-
项目类别:Grant-in-Aid for Scientific Research (C)
-
资助金额:$3.0万
-
财政年份:2017
-
负责人:URAMOTO Hidetaka
-
依托单位:
Analysis of molecular mechanism forEML4-ALK/ EGFR-TKI resistance and establishment of less invasive diagnosis.
-
批准号:25462202
-
项目类别:Grant-in-Aid for Scientific Research (C)
-
资助金额:$3.24万
-
财政年份:2013
-
负责人:URAMOTO Hidetaka
-
依托单位:
Analysis of heterogeneity related g factors in carcinogenesis of lung cancer.
-
批准号:21591831
-
项目类别:Grant-in-Aid for Scientific Research (C)
-
资助金额:$2.75万
-
财政年份:2009
-
负责人:URAMOTO Hidetaka
-
依托单位:
Analysis of cancer related gene as molecular target in malignant pleural mesothelioma.
-
批准号:19591654
-
项目类别:Grant-in-Aid for Scientific Research (C)
-
资助金额:$2.33万
-
财政年份:2007
-
负责人:URAMOTO Hidetaka
-
依托单位:
海外基金